NO20076437L - Anti-GM-CSF antistoffer og anvendelser for disse - Google Patents

Anti-GM-CSF antistoffer og anvendelser for disse

Info

Publication number
NO20076437L
NO20076437L NO20076437A NO20076437A NO20076437L NO 20076437 L NO20076437 L NO 20076437L NO 20076437 A NO20076437 A NO 20076437A NO 20076437 A NO20076437 A NO 20076437A NO 20076437 L NO20076437 L NO 20076437L
Authority
NO
Norway
Prior art keywords
antibodies
csf
various disorders
applications
role
Prior art date
Application number
NO20076437A
Other languages
English (en)
Other versions
NO344992B1 (no
Inventor
Stefan Steidl
Elisabeth Thomassen-Wolf
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of NO20076437L publication Critical patent/NO20076437L/no
Publication of NO344992B1 publication Critical patent/NO344992B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Sammendrag Foreliggende oppfinnelse skaffer til veie rekombinant antigen-bindende regioner, antistoffer og funksjonelle fragmenter av disse som er spesifikke for GM-CSF, som spiller en integrert rolle i forskjellige forstyrrelser og forhold. Disse antistoffene kan således bli anvendt for å behandle, for eksempel inflammatoriske sykdommer slik som reumatoid artritt. Antistoffer fra oppfinnelsen kan også bli anvendt innen det diagnostiske feltet, så vel som for videre undersøkelser av rollen til GM-CSF i utvikling av for skjellige forstyrrelser. Oppfinnelsen skaffer også til veie nukleinsyre sekvenser som koder for foregående antistoffer, vektorer som inneholder det samme, farmasøytiske sammensetninger og kits (sett) med instruksjoner for bruk.
NO20076437A 2005-05-18 2007-12-13 Anti-GM-CSF antistoffer og anvendelser for disse NO344992B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68200905P 2005-05-18 2005-05-18
PCT/EP2006/004696 WO2006122797A2 (en) 2005-05-18 2006-05-17 Anti-gm-csf antibodies and uses therefor

Publications (2)

Publication Number Publication Date
NO20076437L true NO20076437L (no) 2007-12-13
NO344992B1 NO344992B1 (no) 2020-08-17

Family

ID=37114333

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076437A NO344992B1 (no) 2005-05-18 2007-12-13 Anti-GM-CSF antistoffer og anvendelser for disse

Country Status (26)

Country Link
US (5) US7867495B2 (no)
EP (4) EP2468773A3 (no)
JP (2) JP5295759B2 (no)
KR (1) KR101308087B1 (no)
CN (2) CN101218255B (no)
AR (1) AR053608A1 (no)
AU (1) AU2006249062B2 (no)
BR (1) BRPI0610796B8 (no)
CA (1) CA2608498C (no)
CY (2) CY1115920T1 (no)
DK (2) DK3620171T3 (no)
ES (2) ES2527428T3 (no)
HR (2) HRP20150023T1 (no)
HU (1) HUE058876T2 (no)
IL (1) IL187375A (no)
LT (1) LT3620171T (no)
ME (1) ME02059B (no)
NO (1) NO344992B1 (no)
NZ (1) NZ564027A (no)
PL (2) PL3620171T3 (no)
PT (2) PT1888643E (no)
RS (2) RS53743B1 (no)
RU (1) RU2447085C2 (no)
SI (2) SI3620171T1 (no)
TW (1) TWI477512B (no)
WO (1) WO2006122797A2 (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007012569A (es) 2005-04-18 2007-12-06 Micromet Ag Neutralizadores de anticuerpos del factor estimulante de la colonia de macrofagos-granulocitos humanos.
PT1888643E (pt) 2005-05-18 2015-01-14 Morphosys Ag Anticorpos anti-fec-gm e as respectivas utilizações
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
KR101486183B1 (ko) * 2006-02-08 2015-01-28 모르포테크, 인크. 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체
US20080171038A1 (en) * 2006-11-08 2008-07-17 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
CN101605547A (zh) 2006-11-21 2009-12-16 卡罗拜奥斯制药公司 使用gm-csf拮抗剂治疗慢性炎症疾病的方法
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
AU2008253608A1 (en) * 2007-05-23 2008-11-27 Crc For Asthma And Airways Ltd Neutralizing antibodies
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
AU2008323608A1 (en) * 2007-11-12 2009-05-22 Crc For Asthma And Airways Ltd Epitope for neutralizing antibodies
PL2215119T3 (pl) 2007-11-13 2013-06-28 Evec Inc Przeciwciała monoklonalne, które wiążą się z hGM-CSF i kompozycje lecznicze je zawierające
CN104151429B (zh) 2007-11-26 2018-07-10 拜耳知识产权有限责任公司 抗-间皮素抗体及其用途
EP2088432A1 (en) * 2008-02-11 2009-08-12 MorphoSys AG Methods for identification of an antibody or a target
WO2009134805A2 (en) 2008-04-28 2009-11-05 Kalobios Pharmaceuticals, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
WO2009142738A2 (en) * 2008-05-21 2009-11-26 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2010003108A2 (en) * 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. TNF-α ANTAGONIST MULTI-TARGET BINDING PROTEINS
JP5674677B2 (ja) 2008-12-22 2015-02-25 ザ ユニバーシティー オブ メルボルンＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｍｅｌｂｏｕｒｎｅ 疼痛治療
KR101799264B1 (ko) * 2008-12-22 2017-11-20 더 유니버시티 오브 멜버른 골관절염 치료
WO2010124163A2 (en) * 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
JP2012530047A (ja) * 2009-05-05 2012-11-29 モルフォシス・アー・ゲー 多発性硬化症のための治療
EP2729498A1 (en) * 2011-07-06 2014-05-14 MorphoSys AG Therapeutic combinations of anti -cd20 and anti - gm - csf antibodies and uses thereof
US9901079B2 (en) * 2011-08-18 2018-02-27 New York University Inhibition of oncogenic kras-induced GM-CSF production and function
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
CA2871417C (en) 2012-04-23 2021-08-31 Genefrontier Corporation Anti-human cd69 antibody, and use thereof for medical purposes
EP2885639B1 (en) 2012-08-17 2019-04-10 MorphoSys AG Complex-specific antibodies and antibody fragments and their use
HK1208231A1 (en) * 2012-09-20 2016-02-26 Morphosys Ag Treatment for rheumatoid arthritis
KR20210021153A (ko) * 2012-09-20 2021-02-24 모르포시스 아게 류마티스 관절염에 대한 치료
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
EP2918678B1 (en) 2012-11-09 2019-01-30 GeneFrontier Corporation Anti-adam28 antibody for treating cancer
WO2014138862A1 (en) * 2013-03-14 2014-09-18 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
CN105705518A (zh) 2013-08-30 2016-06-22 塔科达有限责任公司 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体
JP6202339B2 (ja) 2013-12-19 2017-09-27 国立研究開発法人国立精神・神経医療研究センター ＧＭ−ＣＳＦ産生Ｔ細胞制御剤、及びＴｈ１／Ｔｈ２免疫バランス調節剤
AU2015257798C1 (en) 2014-05-07 2020-10-22 Takeda Pharmaceutical Company Limited Liquid formulation comprising GM-CSF neutralizing compound
JP6490419B2 (ja) * 2014-12-24 2019-03-27 学校法人関西医科大学 制御性ｔ細胞分化誘導剤
GB201503139D0 (en) * 2015-02-25 2015-04-08 Univ Leicester Diagnostic and therapeutic target
CN107614527A (zh) 2015-03-06 2018-01-19 基因先端领域株式会社 抗人膜类型adam28抗体
KR101953706B1 (ko) * 2016-09-19 2019-03-05 아이-맵 항-gm-csf 항체 및 이것의 사용
CN107840886B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
JP7320498B2 (ja) 2017-10-02 2023-08-03 ヒューマニジェン，インコーポレイテッド Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
WO2020078270A1 (en) 2018-10-15 2020-04-23 Elixiron Immunotherapeutics (hong Kong) Limited Antibodies to granulocyte-macrophage colony stimulating factor and uses thereof
US11078264B2 (en) 2018-10-17 2021-08-03 University Of Connecticut Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
JP7495403B2 (ja) 2018-11-09 2024-06-04 キニクサ ファーマシューティカルズ， リミテッド 巨細胞性動脈炎の治療
US20220096548A1 (en) * 2019-01-07 2022-03-31 Hunan Siweikang Therapeutics Co. Ltd. Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy
CN118949031A (zh) 2019-06-03 2024-11-15 基尼克萨制药股份有限公司 用gm-csf拮抗剂治疗癌症
WO2021188409A1 (en) 2020-03-15 2021-09-23 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
US20220184179A1 (en) 2020-10-26 2022-06-16 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists
NL2036015B1 (en) 2023-10-12 2025-04-30 Micronit Holding B V A method of manufacturing a nozzle assembly, comprising weakening a wafer at at least two focal zones in the depth direction by focusing a laser beam
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5747032A (en) 1990-08-10 1998-05-05 Amrad Corporation Limited Monoclonal antibody to human granulocyte macrophage colony stimulating factor
CA2060741A1 (en) 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
AU781396B2 (en) 1999-07-20 2005-05-19 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
JP2006500905A (ja) 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体
DE60329526D1 (de) 2002-11-15 2009-11-12 Morphotek Inc Verfahren zur erzeugung einer hohen antikörperproduktion von durch in-vitro-immunisierung entstandenen hybridomen
ATE435238T1 (de) 2004-05-05 2009-07-15 Micromet Ag Herstellung eines einkettigen fv antikörperfragments
PT1888643E (pt) * 2005-05-18 2015-01-14 Morphosys Ag Anticorpos anti-fec-gm e as respectivas utilizações

Also Published As

Publication number Publication date
AR053608A1 (es) 2007-05-09
US20210347879A1 (en) 2021-11-11
US20090053213A1 (en) 2009-02-26
JP2013116912A (ja) 2013-06-13
JP2008545632A (ja) 2008-12-18
ES2918209T3 (es) 2022-07-14
CY1125427T1 (el) 2025-05-09
PL3620171T3 (pl) 2022-08-08
WO2006122797A3 (en) 2007-02-15
KR101308087B1 (ko) 2013-10-16
CA2608498A1 (en) 2006-11-23
RU2447085C2 (ru) 2012-04-10
EP3150221A1 (en) 2017-04-05
EP3620171B1 (en) 2022-04-20
CY1115920T1 (el) 2017-01-25
HRP20220755T3 (hr) 2022-09-02
PT1888643E (pt) 2015-01-14
NZ564027A (en) 2011-06-30
US11028165B2 (en) 2021-06-08
BRPI0610796B1 (pt) 2020-01-21
PT3620171T (pt) 2022-06-30
HRP20150023T1 (hr) 2015-02-27
JP5295759B2 (ja) 2013-09-18
US7867495B2 (en) 2011-01-11
CN101218255A (zh) 2008-07-09
ES2527428T3 (es) 2015-01-23
TW200716674A (en) 2007-05-01
HUE058876T2 (hu) 2022-09-28
SI1888643T1 (sl) 2015-03-31
IL187375A (en) 2012-06-28
WO2006122797B1 (en) 2007-04-19
CN101218255B (zh) 2013-01-09
US20110045000A1 (en) 2011-02-24
CA2608498C (en) 2017-04-04
LT3620171T (lt) 2022-06-10
RU2007147870A (ru) 2009-06-27
EP1888643A2 (en) 2008-02-20
EP2468773A3 (en) 2012-09-19
AU2006249062A1 (en) 2006-11-23
US20200024340A1 (en) 2020-01-23
PL1888643T3 (pl) 2015-04-30
EP1888643B1 (en) 2014-10-29
IL187375A0 (en) 2008-02-09
RS63382B1 (sr) 2022-08-31
CN103087190B (zh) 2016-08-03
JP5769744B2 (ja) 2015-08-26
US20170218061A1 (en) 2017-08-03
BRPI0610796A2 (pt) 2010-11-09
US9751939B2 (en) 2017-09-05
KR20080015008A (ko) 2008-02-15
RS53743B1 (sr) 2015-06-30
SI3620171T1 (sl) 2022-09-30
TWI477512B (zh) 2015-03-21
HK1114620A1 (en) 2008-11-07
ME02059B (me) 2015-05-20
NO344992B1 (no) 2020-08-17
AU2006249062B2 (en) 2012-12-20
EP3620171A1 (en) 2020-03-11
DK3620171T3 (da) 2022-06-07
BRPI0610796B8 (pt) 2021-05-25
DK1888643T3 (en) 2015-01-05
US10377820B2 (en) 2019-08-13
WO2006122797A2 (en) 2006-11-23
EP2468773A2 (en) 2012-06-27
CN103087190A (zh) 2013-05-08

Similar Documents

Publication Publication Date Title
NO20076437L (no) Anti-GM-CSF antistoffer og anvendelser for disse
NO20063986L (no) Anti-CD-38-humane antistoffer og anvendelse derav
CY1116377T1 (el) Αναστολεις της ανθρωπινης πρωτεϊνικης φωσφατασης της τυροσινης και μεθοδοι χρησης
ATE475672T1 (de) Anti-il-23-antikörper
EA200870050A1 (ru) Анти-il-17-антитела
UA100377C2 (en) Antibodies against il-25
NO20091283L (no) Humane antistoffer som binder CXCR4 og anvendelser derav
MA32771B1 (fr) Mutants fgf21 et leurs utilisations
TN2010000234A1 (en) Anti-mesothelin antibodies and uses therefor
CL2007001840A1 (es) Anticuerpo neutralizante que se une a la interleuquina 17 humana (il-17); secuencia de adn que lo codifica; vector y celula huesped que la comprenden; proceso de produccion; preparacion farmaceutica que lo comprende; y su uso para el tratamiento o profilaxis de patologias mediadas por il-17.
MX2010003574A (es) Anticuerpos il-23.
NO20073981L (no) Criptobindende molekyler
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
NO20080246L (no) Anti-IGF1R-antistofformuleringer
EA201690946A1 (ru) Мутанты fgf21 и их применение
UA100682C2 (ru) АНТИТЕЛО, КОТОРОЕ НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ ЦИТОМЕГАЛОВИРУС (hCMV), И ЕГО ПРИМЕНЕНИЕ
EA019476B9 (ru) АНТИТЕЛА ПРОТИВ IL-23p19 И ИХ ПРИМЕНЕНИЕ
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
EA200970765A1 (ru) 2-аминопиримидиновые модуляторы рецептора hгистамина
EA200702532A1 (ru) Антитела против мср-1, композиции, способы и применения
UA105384C2 (ru) Лечение нарушений, связанных с инсулинорезистентностью
NO20083751L (no) Metoder for behandling av kognitive og andre sykdommer
WO2007119029A8 (fr) Co-cristaux de calixarenes et de molecules biologiquement actives
DE602006016736D1 (de) Für lipopolysaccharide (lps) des pseudomonas aeruginosa-iats-o11-serotyps spezifische humane monoklonale antikörper
UA99714C2 (ru) Моноклональное антитело, которое специфически связывается с light

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MORPHOSYS AG, DE